Skip to main content
    U

    United Therapeutics Corporation (UTHR)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $541.51
    +1.48 (+0.27%)

    Market Cap: $23.16B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(21/39)
    Avg Surprise
    -13.75%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$6.21
    Range$4.40 - $7.26
    14 analysts
    EPS RevisionsNo revisions (7d)
    4
    7
    30d
    EPS Estimate DriftChange to current
    90d ago$7.00-11.3%
    60d ago$6.45-3.6%
    30d ago$6.44-3.5%
    7d ago$6.46-3.8%
    Current$6.21
    Revenue Consensus
    $785M
    Range$751M - $807M
    13 analysts
    Period ending Dec 31, 2026
    EPS Consensus$6.23
    Range$2.72 - $8.75
    14 analysts
    Revenue Consensus
    $772M
    Range$660M - $935M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$6.23---
    Sep 26EST
    		-$6.21---
    Jun 26
    Reported Aug 5
    		$7.27$6.82+6.60%Beat+13.4%
    Mar 26
    Reported May 6
    		$5.82$6.86-15.16%Miss-12.2%
    Dec 25
    Reported Feb 25
    		$7.70$7.10+8.45%Beat+24.4%
    Sep 25
    Reported Oct 29
    		$7.16$6.96+2.87%Beat+1.3%
    Jun 25
    Reported Jul 30
    		$6.41$7.30-12.19%Miss+9.6%
    Mar 25
    Reported Apr 30
    		$6.63$6.54+1.38%Beat+7.5%
    Dec 24
    Reported Feb 26
    		$6.19$6.27-1.23%Miss+42.0%
    Sep 24
    Reported Oct 30
    		$7.07$7.12-0.70%Miss+31.4%
    Jun 24
    Reported Jul 31
    		$5.85$6.41-8.74%Miss+11.6%
    Mar 24
    Reported May 1
    		$6.17$5.59+10.38%Beat+27.0%
    Dec 23
    Reported Feb 21
    		$4.36$4.19+4.06%Beat+63.3%
    Sep 23
    Reported Nov 1
    		$5.38$5.04+6.75%Beat+9.6%
    Jun 23
    Reported Aug 2
    		$5.24$4.78+9.62%Beat+51.4%
    Mar 23
    Reported May 3
    		$4.86$4.71+3.18%Beat-3.4%
    Dec 22
    Reported Feb 22
    		$2.67$4.51-40.80%Miss+13.6%
    Sep 22
    Reported Nov 2
    		$4.91$3.77+30.24%Beat+43.6%
    Jun 22
    Reported Aug 3
    		$3.46$4.54-23.79%Miss-15.4%
    Mar 22
    Reported May 4
    		$5.03$3.07+63.84%Beat+44.1%
    Dec 21
    Reported Feb 24
    		$2.35$3.72-36.83%Miss+7.3%
    Sep 21
    Reported Nov 3
    		$3.42$3.58-4.47%Miss-11.9%
    Jun 21
    Reported Aug 4
    		$4.09$3.56+14.89%Beat+11.1%
    Mar 21
    Reported May 5
    		$3.49$3.49+0.00%Beat-3.3%
    Dec 20
    Reported Feb 24
    		$2.19$3.14-30.25%Miss+82.5%
    Sep 20
    Reported Oct 28
    		$3.88$3.34+16.17%Beat+1.3%
    Jun 20
    Reported Jul 29
    		$3.68$3.28+12.20%Beat+1.4%
    Mar 20
    Reported Apr 29
    		$3.61$3.39+6.49%Beat+131.9%
    Dec 19
    Reported Feb 26
    		$1.20N/A-55.22%Miss-18.9%
    Sep 19
    Reported Oct 30
    		$3.83$2.90+32.07%Beat+58.3%
    Jun 19
    Reported Jul 31
    		$3.63$2.74+32.48%Beat-16.7%
    Mar 19
    Reported May 1
    		$-11.32$2.77-508.66%Miss-401.1%
    Dec 18
    Reported Feb 27
    		$1.48$2.55-41.96%Miss-62.0%
    Sep 18
    Reported Oct 31
    		$2.42$3.03-20.13%Miss-48.4%
    Jun 18
    Reported Aug 1
    		$4.36$3.42+27.49%Beat-0.2%
    Mar 18
    Reported May 2
    		$3.76$4.00-6.00%Miss+4.2%
    Dec 17
    Reported Feb 21
    		$3.89$3.89+0.00%Beat+56.2%
    Sep 17
    Reported Oct 25
    		$4.69$4.80-2.29%Miss-
    Jun 17
    Reported Jul 27
    		$4.37$3.66+19.40%Beat-
    Mar 17
    Reported Apr 26
    		$3.61$3.82-5.50%Miss-
    Dec 16
    Reported Feb 22
    		$2.49$3.61-31.02%Miss-

    Key Metrics

    Valuation
    P/E Ratio19.37EV/EBITDA14.05x
    Price/FCF21.11xFCF Yield4.74%
    Profitability
    Profit Margin41.60%Operating Margin42.20%
    ROE19.30%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage118.51x
    Current Ratio5.73xQuick Ratio5.41x
    Trading Statistics
    Beta0.49Avg Volume989.46K
    52-Week High$609.3552-Week Low$409.07

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$542.17
    SMA 20$521.22
    SMA 50$514.66
    SMA 200$526.82
    EMA 10$538.28
    EMA 20$528.84
    EMA 50$521.95
    EMA 200$508.83

    MACD

    Line: 10.65Signal: 8.59Hist: 2.06

    ADX

    ADX: 22.4+DI: 28.4-DI: 25.3

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down40.0
    PSAR$509.30

    Bollinger Bands

    Upper Band$582.77
    Lower Band$459.66
    %B Position2362%(Upper)
    Band Width0.66

    RSI (14-Day)

    Neutral
    56.8

    Momentum Oscillators

    Stoch %K61.9
    Stoch %D64.5
    Williams %R-38.5
    ROC (10d)-5.2%
    Momentum-29.87
    CCI (20d)54.3
    MFI (14d)57.2

    Volatility Measures

    ATR (14d)$18.74(3.5%)
    StdDev (20d)30.78
    Hist Vol57.6%(High)

    Volume Flow

    VWAP$543.80
    OBV9.5M
    AD Line15.0M
    CMF (20d)-0.043

    Volume Metrics

    Avg Vol (20d)991.3K
    Vol Ratio0.5x
    VWMA (20d)$528.43

    Pivot Points

    R3$572.90
    R2$559.90
    R1$549.96
    Pivot Point$536.96
    S1$527.02
    S2$514.02
    S3$504.08

    Advanced Oscillators

    TSI15.01
    Ultimate Osc50.5
    KST69.11

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$783.30M$781.50M$790.20M$799.50M$798.60M$794.40M$735.90M$748.90M$714.90M$677.70M$614.70M$609.40M
    Cost of Revenue$99.50M$133.40M$103.40M$100.90M$87.60M$92.50M$75.90M$83.10M$77.80M$72.90M$71.00M$70.10M
    Gross Profit$683.80M$648.10M$686.80M$698.60M$711.00M$701.90M$660.00M$665.80M$637.10M$604.80M$543.70M$539.30M
    Operating Expenses$353.00M$322.30M$330.10M$310.10M$346.50M$319.10M$302.30M$322.70M$317.20M$248.50M$283.60M$212.30M
    R&D$146.30M$138.20M$139.50M$127.50M$134.00M$149.00M$133.80M$103.50M$139.60M$104.10M$151.40M$84.70M
    SG&A$206.70M$184.10M$190.60M$182.60M$212.50M$170.10M$168.50M$219.20M$177.60M$144.40M$132.20M$127.60M
    Operating Income$330.80M$325.80M$356.70M$388.50M$364.50M$382.80M$357.70M$343.10M$319.90M$356.30M$260.10M$327.00M
    Interest Income$31.50M$41.80M$43.20M$46.40M$51.30M$51.10M$49.30M$49.80M$46.20M$53.80M$51.00M$45.30M
    Interest Expense$2.90M$3.00M$3.10M$3.00M$7.30M$6.10M$7.90M$10.10M$11.60M$13.30M$15.10M$15.60M
    Income Before Tax$372.70M$318.30M$444.00M$438.00M$408.40M$423.50M$396.50M$388.60M$355.30M$398.60M$295.40M$351.80M
    Income Tax Expense$39.70M$43.40M$79.70M$99.30M$98.90M$101.30M$95.20M$79.50M$77.20M$92.00M$78.30M$84.20M
    Net Income$333.00M$274.90M$364.30M$338.70M$309.50M$322.20M$301.30M$309.10M$278.10M$306.60M$217.10M$267.60M
    EBITDA$368.30M$302.10M$426.70M$416.50M$385.50M$398.30M$374.80M$368.00M$339.40M$373.10M$273.20M$335.40M
    EBIT$344.10M$279.50M$403.90M$394.60M$364.40M$378.50M$355.10M$348.90M$320.70M$358.10M$259.50M$322.10M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about UTHR

    Government Contracts

    Gov Obligations (TTM)
    $1.32M
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    75
    New Awards (TTM)
    72
    Avg Remaining Term
    1.9 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26026F0064Department of Veterans AffairsDepartment of Veterans Affairs$108435Oct 20, 2025
    36C24526N0777Department of Veterans AffairsDepartment of Veterans Affairs$33158Jul 29, 2026
    36C24526N0702Department of Veterans AffairsDepartment of Veterans Affairs$33158Jul 1, 2026
    36C24526N0701Department of Veterans AffairsDepartment of Veterans Affairs$33158Jul 1, 2026
    36C24526N0620Department of Veterans AffairsDepartment of Veterans Affairs$33158Jun 2, 2026
    36C24526N0606Department of Veterans AffairsDepartment of Veterans Affairs$33158May 28, 2026
    36C24526N0557Department of Veterans AffairsDepartment of Veterans Affairs$33158Apr 30, 2026
    36C24526N0556Department of Veterans AffairsDepartment of Veterans Affairs$33158Apr 28, 2026
    36C24526N0466Department of Veterans AffairsDepartment of Veterans Affairs$33158Apr 3, 2026
    36C24526N0704Department of Veterans AffairsDepartment of Veterans Affairs$17614Jul 1, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 14 October

    This article reports on a Form 4 filing for United Therapeutics Corporation, specifically detailing activity by Martine A. Rothblatt, who serves as Director...

    Investing.com Nigeria•10/15/26•Neutral

    After exercising options at $117.76, United Therapeutics (UTHR) CEO family trusts sell 9,500 shares.

    Family trusts associated with Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), exercised 9,500 stock options at $117.76 per share on October 14, 2026...

    Stock Titan•10/15/26•Neutral

    A CEO trust exercises options at $117.76 and sells 9,500 United Therapeutics (UTHR) shares.

    A family trust associated with United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at $117.76 per share and subsequently sold 9,500 common shares. The sales...

    Stock Titan•10/15/26•Somewhat-Bullish

    Liquidia shares surge 25% as settlement ends United Therapeutics litigation

    Liquidia shares surged 25% after settling all six lawsuits with United Therapeutics Corporation, resolving years of patent and antitrust disputes. The settlement, totaling $380.7 million payable through April 2027...

    Yahoo! Finance Canada•10/14/26•Neutral

    Why Is Liquidia Stock Skyrocketing Wednesday? - United Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA)

    Liquidia Corporation's stock surged nearly 40% after announcing a $380.7 million settlement with United Therapeutics...

    Benzinga•10/14/26•Somewhat-Bullish

    UTHR Valuation and Fair Value

    P/E
    19.4x
    Forward P/E
    16.4x
    EV/EBITDA
    14.0x
    P/FCF
    21.1x
    PEG
    2.2x
    P/B
    3.6x
    See GNG's fair value

    UTHR Profitability: Margins, ROIC and FCF

    Gross margin
    86.1%
    Operating margin
    42.2%
    Net margin
    41.6%
    ROE
    19.3%
    FCF margin
    34.6%
    FCF yield
    4.7%

    UTHR Competitors

    CompanyTicker
    Koninklijke Philips NV ADRPHG
    Genmab ASGMAB
    Roivant Sciences LtdROIV
    Incyte CorporationINCY
    Quest Diagnostics IncorporatedDGX
    Tenet Healthcare CorporationTHC
    Laboratory Corporation of America HoldingsLH
    Insmed IncINSM

    Sector: Healthcare

    UTHR Analyst Ratings

    Consensus
    Buy
    Analysts
    15
    Strong Buy
    3
    Buy
    8
    Hold
    3
    Sell
    1
    Strong Sell
    0

    UTHR Bull Case vs Bear Case

    Bull case

    • UTHR converts 34.6% of revenue into free cash flow.
    • UTHR has a 41.6% net profit margin.
    • 73.3% of UTHR's analyst ratings are Buy or Strong Buy.

    Bear case

    • UTHR's quarterly revenue changed -1.9% year over year.

    UTHR Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -1.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $6.21
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    4 up, 7 down

    Frequently Asked Questions About UTHR

    Does UTHR pay dividends?

    United Therapeutics Corporation (UTHR) does not currently pay a regular dividend.

    What is UTHR's P/E ratio?

    United Therapeutics Corporation has a price-to-earnings (P/E) ratio of 19.37.

    What is UTHR's market cap?

    United Therapeutics Corporation (UTHR) has a market capitalization of $23.16B with a current stock price of $541.51.

    Related stocks

    Sector: Healthcare

    All stocks starting with U

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In